Meduloc Secures $4M to Launch Novel Fracture Fixation Tech, Backed by MLB Star

WEST CHESTER, PA – August 06, 2026 – Orthopedic medical device company Meduloc today announced the closing of a $4 million Series B financing round, a strategic infusion of capital that moves its innovative fracture fixation platform from development to the doorstep of the clinical market. The round was led by GenHenn Capital and features a diverse syndicate of investors, including former Major League Baseball All-Star Andre Ethier.

The funding is earmarked to initiate a controlled alpha launch of the company's FDA-cleared technology, a flexible nitinol intramedullary implant designed to revolutionize the treatment of long-bone fractures. This financing marks a critical inflection point for the West Chester-based firm, enabling it to build crucial clinical evidence and develop the commercial infrastructure needed for a broader market entry.

"Closing this financing is a significant milestone for Meduloc as we move from product development and regulatory clearance into controlled commercialization," said Sarah Sachinis, President and CEO of Meduloc.

A New Era in Fracture Fixation?

At the heart of Meduloc's strategy is a technology that aims to create a new standard of care for certain fractures. The company's platform, which received FDA 510(k) clearance in November 2025, is a sterile, single-use system for treating fractures in small, long bones like the metacarpal, radius, ulna, and fibula in both adult and pediatric patients.

The system’s innovation lies in its core component: a flexible implant made of nitinol, a nickel-titanium alloy renowned for its superelasticity and shape-memory properties. This allows the implant to be navigated into the intramedullary canal of a bone in a flexible state before deploying a prong locking mechanism to provide immediate rotational and length stability to the fracture.

This approach offers significant clinical advantages over some traditional fixation methods, such as plates and screws. According to the company, the minimally invasive technique is designed to preserve anatomy and, crucially, avoid violating the joint capsule in certain applications. This differentiation could translate into substantial patient benefits, including the potential for earlier mobility, reduced surgical complexity, and a faster overall recovery with fewer complications. The use of nitinol also offers continuous dynamic compression across the fracture site, which can promote healing, and its flexibility helps reduce "stress shielding," a phenomenon where overly rigid implants carry too much load, preventing the bone from maintaining its natural density.

"Meduloc has developed a differentiated technology with the potential to address important needs in fracture fixation," said Bill Hagaman of GenHenn Capital. "With FDA clearance, encouraging early clinical experience and an experienced team, the company has reached an exciting inflection point."

Pennsylvania's Med-Tech Hub Fuels Growth

The $4 million financing is not just a testament to Meduloc's technology but also a reflection of a thriving regional life sciences ecosystem. The participation of Pennsylvania-based investors—including Life Sciences Greenhouse Investments (LSGI), Ben Franklin Technology Partners of Southeastern Pennsylvania, and Broad Street Angels—signals strong local confidence in the company's trajectory.

This regional backing is more than just capital; it represents a strategic partnership. Both LSGI and Ben Franklin Technology Partners noted that their investments were financed in part by grants from the Commonwealth of Pennsylvania, highlighting a concerted public-private effort to cultivate innovation and economic growth in the Greater Philadelphia area. Such initiatives are crucial for early-stage companies like Meduloc, providing the resources needed to navigate the capital-intensive path from regulatory approval to commercial success.

"We are extremely grateful for the confidence and support of our investors, and particularly proud of the strong backing we have received from the Greater Philadelphia and Pennsylvania life sciences and investment communities," Sachinis stated. This local support system provides a powerful foundation as the company prepares to scale its operations.

From the Diamond to Device Investment

Adding a unique dimension to the investor group is Andre Ethier, a former two-time MLB All-Star with the Los Angeles Dodgers. His involvement underscores a growing trend of professional athletes investing in cutting-edge medical technologies, often driven by personal experience with the physical demands of their careers.

For athletes, injuries are not an abstraction but a tangible threat to performance and livelihood. The recovery process is a critical, often arduous journey, giving them a firsthand appreciation for innovations that can improve outcomes.

"As a former professional athlete, I have seen how injuries and recovery can affect both performance and quality of life," Ethier explained. "Meduloc's approach stood out to me because of its potential to provide surgeons with an innovative treatment option and help patients return to the activities that matter to them. I'm excited to support the team as it brings this technology into broader clinical use."

Ethier's endorsement lends not only financial support but also a powerful narrative and public visibility to Meduloc's mission, connecting the clinical benefits of its device to the relatable goal of a quick and effective return to an active life.

Charting the Path to Market

With capital secured, Meduloc is poised to execute the next phase of its growth strategy. The company plans to begin its controlled alpha launch in early August, collaborating with a select group of orthopedic surgeons and institutions. This initial rollout is designed to build a repository of clinical experience across multiple fracture applications while gathering direct feedback from the surgeons who will ultimately use the device. This data will be invaluable for refining surgical techniques and informing the company's future commercial expansion.

The firm is entering a large and competitive market. The global orthopedic trauma fixation device market was valued at approximately $7.8 billion in 2025 and is projected by some analysts to grow at a CAGR of over 5% through the next decade, driven by an aging population and a rising incidence of traumatic injuries. The space is dominated by industry giants like Johnson & Johnson MedTech and Stryker, which offer extensive portfolios of fixation devices.

However, Meduloc's leadership believes its specialized technology addresses key unmet needs, particularly for small bone fractures where avoiding joint disruption is paramount. The capital from this Series B round will enable the company to build the commercial infrastructure required to bring its fracture fixation platform to a broader audience of surgeons and patients, establishing a foothold in this dynamic market. This funding enables the company to begin its alpha launch, build meaningful clinical experience and establish the foundation for broader adoption across adult and pediatric fracture care.